| Title |
Challenges towards targeted drug delivery in cancer nanomedicines / |
| Authors |
Hafeez, Muhammad Nadeem ; Celia, Christian ; Petrikaitė, Vilma |
| DOI |
10.3390/pr9091527 |
| Full Text |
|
| Is Part of |
Processes.. Basel : MDPI. 2021, vol. 9, iss. 9, art. no. 1527, p. [1-16].. eISSN 2227-9717 |
| Keywords [eng] |
Clinical translational ; Nano-drug ; Nanocarrier ; Nanomedicine ; Targeted delivery |
| Abstract [eng] |
Despite cancer nanomedicine celebrates already thirty years since its introduction, together with the achievements and progress in cancer treatment area, it still undergoes serious disadvantages that must be addressed. Since the first observation that macromolecules tend to accumulate in tumor tissue due to fenestrated endothelial of vasculature, considered as the “royal gate” in drug delivery field, more than dozens of nanoformulations have been approved and introduced into the practice for cancer treatment. Lipid, polymeric, and hybrid nanocarriers are biocompatible nano-drug delivery systems (NDDs) having suitable physicochemical properties and modulate payload release in response to specific chemical or physical stimuli. Biopharmaceutical properties of NDDs and their efficacy in animal models and humans can significantly affect their impact and perspective in nanomedicine. One of the future directions could be focusing on personalized cancer treatment, considering the heterogeneity and complexity of each patient tumor tissue and the designing of multifunctional targeted NDDs combining synthetic nanomaterials and biological components, like cellular membranes, circulating proteins, RNAi/DNAi, which enforce the efficacy of NDDs and boost their therapeutic effect. |
| Published |
Basel : MDPI |
| Type |
Journal article |
| Language |
English |
| Publication date |
2021 |
| CC license |
|
